New combo aims to zap tumors, save kidneys
NCT ID NCT07233252
Summary
This study is testing whether a combination of two drugs, tislelizumab and nab-paclitaxel, can effectively treat a type of kidney cancer located in the renal pelvis. The main goal is to control the cancer for at least one year while avoiding the need to surgically remove the entire kidney. About 35 patients with specific, early-stage tumors will receive the drug treatment, followed by a minimally invasive laser procedure if needed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TISLELIZUMAB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Hospital of Tianjin Medical University
RECRUITINGTianjin, Outside U.S., 300211, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.